MaxCyte Forecasts Stable Revenue Amid Strategic Realignment.

lunes, 12 de enero de 2026, 11:24 pm ET1 min de lectura
MXCT--

MaxCyte (MXCT) forecasts Q4 core revenue of $6.6-6.7mln, FY22 core revenue of $29.5-29.6mln, and SPL program revenue of $3.3-3.5mln. By 2025, the company expects total cash, cash equivalents, and investments to reach $155.6mln. Despite macroeconomic challenges, MaxCyte anticipates stable revenue and a strong financial position.

MaxCyte Forecasts Stable Revenue Amid Strategic Realignment.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios